Replies to post #502072 on Anavex Life Sciences Corp (AVXL)

[boi568]

ADL is not an EMA requirement for the early AD trial Anavex conducted.

[williamssc]

The cognitive endpoint ADAS-Cog13 showed statistically significant slowing of decline. The ADCS-ADL did show to trend upward. In the OLE, ADCS-ADL differences became more favorable over time even reaching reaching stat sig. It's been pointed out that subtle changes in daily living are harder for family members to detect in the short term. So we have a safe effective oral treatment going before regulators.